Analyzing Xenon Pharmaceuticals (XENE) and The Competition
Xenon Pharmaceuticals (NASDAQ: XENE) is one of 293 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Xenon Pharmaceuticals to similar companies based on the strength of its analyst recommendations, risk, institutional ownership, dividends, valuation, earnings and profitability.
This is a breakdown of recent ratings and price targets for Xenon Pharmaceuticals and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Xenon Pharmaceuticals Competitors||755||3009||11122||226||2.72|
Xenon Pharmaceuticals currently has a consensus target price of $10.63, suggesting a potential upside of 226.92%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 33.39%. Given Xenon Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts plainly believe Xenon Pharmaceuticals is more favorable than its rivals.
Risk & Volatility
Xenon Pharmaceuticals has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals’ rivals have a beta of 6.66, meaning that their average stock price is 566% more volatile than the S&P 500.
This table compares Xenon Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Xenon Pharmaceuticals Competitors||-5,532.02%||-454.26%||-42.36%|
Insider & Institutional Ownership
55.3% of Xenon Pharmaceuticals shares are held by institutional investors. Comparatively, 51.0% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 9.4% of Xenon Pharmaceuticals shares are held by insiders. Comparatively, 16.9% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Xenon Pharmaceuticals and its rivals revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Xenon Pharmaceuticals||$819,999.00||-$28.01 million||-1.95|
|Xenon Pharmaceuticals Competitors||$261.64 million||$67.77 million||-6.95|
Xenon Pharmaceuticals’ rivals have higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Xenon Pharmaceuticals Company Profile
Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD). Specifically, it is intended to treat LPLD in patients with severe or multiple pancreatitis attacks, despite dietary fat restrictions. TV-45070 is a small-molecule inhibitor of the sodium channel Nav1.7 and other sodium channels, including those that are expressed in the pain-sensing peripheral nervous system. XEN901 is developed for the treatment of rare infantile epileptic encephalopathy and other forms of epilepsy. XEN1101, is a potassium channel modulator for the treatment of epilepsy. Its Extreme Genetics discovery platform enables the Company to identify drug targets that are more biologically relevant in humans.
Receive News & Ratings for Xenon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.